IQVIA Holdings Inc.'s Stock Analysis

IQVIA Holdings Raises €950 Million Through Senior Notes Offering

IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., has successfully issued €950,000,000 in 4.625% senior notes due 2033. The net proceeds from this offering will primarily be used to refinance existing debt and cover related fees and expenses. The notes are unsecured and will bear interest payable semi-annually, starting December 15, 2026.

The notes can be redeemed before their maturity date, with specific terms regarding premiums. The initial period for redemption without a premium extends until June 15, 2029, after which the redemption premium will decrease. This offering may influence the company’s financial leverage and liquidity positioning in the market.

Jun 11, 2026 16:46:50

IQVIA Holdings Prices €950 Million Senior Notes Offering

IQVIA Holdings Inc. announced the pricing of €950,000,000 in senior notes due 2033, with an interest rate of 4.625% per annum. The proceeds from this offering will be utilized to refinance existing debt and cover related fees and expenses. The notes will pay interest semi-annually, starting December 15, 2026, and are set to mature on June 15, 2033, pending standard closing conditions.

The issuance of these notes is targeted for June 11, 2026, and will be offered primarily to qualified institutional buyers in the United States and non-U.S. investors outside the United States. These notes have not been registered under the Securities Act and are being sold through a private offering memorandum. IQVIA Holdings operates as a global provider of clinical research services and healthcare intelligence, employing approximately 93,000 individuals across over 100 countries.

Jun 04, 2026 17:08:13

IQVIA Increases Stock Repurchase Authorization by $2 Billion

IQVIA Holdings Inc. announced that its board of directors has authorized an additional $2 billion for the company's existing equity repurchase program, increasing the total remaining authorization to $3.2 billion. The repurchase program allows for flexibility, as it does not obligate the company to buy back any specific amount of common stock, and it can be modified or discontinued at any time based on management's assessment of market conditions and corporate needs.

The company may execute stock repurchases through various methods, including open market transactions and privately negotiated deals. There is no expiration date for the repurchase program, and IQVIA has indicated that it may also engage in additional repurchases outside of this program. The company's management will determine the timing and amount of any stock buybacks, which could influence investor sentiment and stock price.

May 07, 2026 17:24:37

IQVIA Increases Share Buyback Authorization by $2 Billion

IQVIA Holdings Inc. has announced that its board of directors has authorized an additional $2 billion for the repurchase of the company's common stock, increasing the total remaining authorization to $3.2 billion under its existing equity repurchase program. The program allows for stock repurchases to be made at management's discretion, based on various factors including market conditions and corporate requirements, and does not have a set expiration date.

The repurchase program does not obligate IQVIA to buy back a specific amount of shares and can be modified or suspended at any time. The company may also engage in stock repurchases outside of the formal program through private or other transactions. Investors should note that repurchases may be discontinued without prior notice.

May 07, 2026 17:24:37

IQVIA Reports First Quarter 2026 Financial Results and Guidance

IQVIA Holdings Inc. reported its financial results for the first quarter of 2026, with total revenue reaching $4,151 million, an increase of 8.4% compared to the previous year. The company achieved a GAAP net income of $274 million and an adjusted EBITDA of $932 million. Revenue from Commercial Solutions rose by 11.6% to $1,754 million, while Research & Development Solutions increased by 6.2% to $2,397 million. The company also reported a contracted backlog of $34.2 billion in R&D Solutions, with new bookings of $2.5 billion during the quarter. Operating cash flow was $618 million, and free cash flow was $491 million, representing a 15% year-over-year increase.

Additionally, IQVIA has reaffirmed its full-year guidance for 2026, projecting revenue between $17,150 million and $17,350 million, and adjusted EBITDA between $3,975 million and $4,025 million. The company raised its adjusted diluted earnings per share guidance to a range of $12.65 to $12.95. During the quarter, IQVIA repurchased $552 million of its common stock, with $1,217 million remaining under its share repurchase authorization as of March 31, 2026.

May 05, 2026 07:03:40

IQVIA Holdings Approves 2026 Incentive and Stock Award Plan

On April 23, 2026, IQVIA Holdings Inc. held its Annual Meeting where stockholders approved the 2026 Incentive and Stock Award Plan, which replaces the 2017 Plan. The new plan includes various performance- and time-based equity awards, such as stock options and restricted stock units, with vesting dependent on the company's performance metrics determined by the Leadership Development and Compensation Committee.

Additionally, stockholders elected board nominees, approved the 2025 compensation for named executives, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026. As of February 23, 2026, there were 167,866,339 shares of common stock outstanding, eligible to vote on these matters.

Apr 23, 2026 16:20:58

IQVIA Reports 2025 Financial Results and 2026 Guidance

IQVIA Holdings Inc. announced its financial results for the fourth quarter and full year of 2025, reporting a revenue of $4,364 million for the fourth quarter and $16,310 million for the full year. The company achieved a GAAP net income of $514 million for the fourth quarter and $1,360 million for the full year, with adjusted diluted earnings per share of $3.42 for the fourth quarter and $11.92 for the full year. The company also reported a strong backlog in its Research & Development Solutions segment, amounting to $32.7 billion, which is expected to convert to revenue over the next year.

For 2026, IQVIA provided revenue guidance between $17,150 million and $17,350 million, alongside an adjusted EBITDA forecast of $3,975 million to $4,025 million. The company anticipates adjusted diluted earnings per share to range from $12.55 to $12.85. Additionally, IQVIA's cash and cash equivalents stood at $1,980 million, with total debt at $15,724 million, indicating a net leverage ratio of 3.63x trailing twelve-month adjusted EBITDA. The company also repurchased $1,244 million of its common stock in 2025, with $1,769 million of share repurchase authorization remaining.

Feb 05, 2026 07:04:04

IQVIA Holdings Refinances Credit Agreement with New Terms

On December 9, 2025, IQVIA Holdings Inc. amended its Fifth Amended and Restated Credit Agreement to refinance existing loans into new classes, including Term A dollar loans and revolving credit commitments. This amendment also includes a reduction in interest rates for U.S. dollar-denominated loans by eliminating the term SOFR credit spread adjustment.

Additionally, the amendment releases the Swiss Subsidiary Borrower and the Japanese Borrower from all obligations under the Credit Agreement. These changes may impact the company's financial obligations and overall debt structure.

Dec 09, 2025 16:55:11

IQVIA Appoints Dr. William G. Kaelin Jr. to Board

IQVIA Holdings Inc. has appointed Dr. William G. Kaelin Jr. to its Board of Directors effective November 5, 2025. Dr. Kaelin is recognized for his expertise in oncology and biomedical innovation, having received the Nobel Prize in Physiology or Medicine in 2019 for his work on oxygen sensing. He currently serves as a Senior Physician-Scientist at Brigham and Women’s Hospital and holds a significant role on the board of Eli Lilly and Company.

Dr. Kaelin's appointment is expected to enhance IQVIA's strategic direction, particularly in clinical research and healthcare intelligence. The company emphasizes its commitment to using advanced technologies and AI responsibly to improve patient outcomes and population health. With a workforce of approximately 91,000 employees globally, IQVIA aims to leverage its resources and insights to support healthcare stakeholders in advancing medical treatments.

Nov 05, 2025 16:29:39

IQVIA Reports Third Quarter 2025 Financial Results and Guidance

IQVIA Holdings Inc. reported a revenue of $4.1 billion for the third quarter of 2025, marking a 5.2 percent increase year-over-year. The company achieved a GAAP net income of $331 million, with diluted earnings per share at $1.93. The Research & Development Solutions segment showed a contracted backlog of $32.4 billion, up 4.1 percent year-over-year, and net new bookings reached $2.6 billion, resulting in a book-to-bill ratio of 1.15x. Free cash flow also saw significant growth, reaching $772 million, which is a 35 percent increase compared to the previous year.

For the first nine months of 2025, IQVIA's total revenue was $11.946 billion, a 4.4 percent rise from the same period in 2024. The company reaffirmed its full-year financial guidance, projecting revenues between $16.15 billion and $16.25 billion, and adjusted EBITDA between $3.775 billion and $3.8 billion. As of September 30, 2025, IQVIA reported cash and cash equivalents of $1.814 billion against total debt of $14.957 billion, resulting in a net debt of $13.143 billion.

Oct 28, 2025 07:05:04